Literature DB >> 23590777

Novel articulating medullary-sparing spacer for the treatment of infectious hip arthritis.

Hao Shen1, Qiao-Jie Wang, Xian-Long Zhang, Yao Jiang.   

Abstract

Two-stage total hip arthroplasty (THA) is considered a safe choice for the treatment of primary infectious arthritis of the hip. In cases where the proximal portion of the femur is intact without infection, the use of a spacer with a femoral stem during the interim would disturb the normal femoral medullary cavity. The authors report the technical procedure and outcomes of cases using a novel medullary sparing, antibiotic-loaded hip spacer for the treatment of hip infections.Five consecutive patients (5 hips) with infectious arthritis of the hip were treated in a 2-stage approach using an intraoperatively made medullary-sparing hip spacer. During the first-stage THA, after thorough debridement of potentially infected and necrotic soft tissues, the spacer was inserted into the femoral neck and fixed without opening the femoral canal. Antibiotics were administered for at least 6 weeks and were continued until the infection was controlled clinically, after which the second-stage THA was completed.Infection was eradicated in all 5 hips. Average follow-up was 39.6 months (range, 30-59 months). At most recent follow-up, no recurrence of infection was observed. No specific complications were associated with the use of this novel spacer. Average Harris Hip Score improved from 35.2 (range, 28-43) before the first-stage THA to 61.6 (range, 54-71) between the 2 stages and to 93.6 (range, 89-99) at final follow-up. All patients ambulated with the aid of crutches during the interim period. Copyright 2013, SLACK Incorporated.

Entities:  

Mesh:

Year:  2013        PMID: 23590777     DOI: 10.3928/01477447-20130327-13

Source DB:  PubMed          Journal:  Orthopedics        ISSN: 0147-7447            Impact factor:   1.390


  7 in total

Review 1.  Two-stage arthroplasty for septic arthritis of the hip and knee: A systematic review on infection control and clinical functional outcomes.

Authors:  Antonio Russo; Luca Cavagnaro; Mattia Alessio-Mazzola; Lamberto Felli; Giorgio Burastero; Matteo Formica
Journal:  J Clin Orthop Trauma       Date:  2021-11-30

2.  Surgical Management for Chronic Destructive Septic Hip Arthritis: Debridement, Antibiotics, and Single-Stage Replacement is as Effective as Two-Stage Arthroplasty.

Authors:  Chao-Fan Zhang; Xin-Yu Fang; Zi-da Huang; Guo-Chang Bai; Ze-Yu Zhang; Ye Yang; Zi-Jie Zhang; Wen-Bo Li; Wen-Ming Zhang
Journal:  Orthop Surg       Date:  2022-05-18       Impact factor: 2.279

3.  High 2-year mortality and recurrent infection rates after surgical treatment for primary septic arthritis of the hip in adult patients: An observational study.

Authors:  Feng-Chen Kao; Yao-Chun Hsu; Pao-Hsin Liu; Yuan-Kun Tu; I-Ming Jou
Journal:  Medicine (Baltimore)       Date:  2019-08       Impact factor: 1.817

Review 4.  Active septic arthritis of the hip in adults: what's new in the treatment? A systematic review.

Authors:  Fabio D'Angelo; Luca Monestier; Luigi Zagra
Journal:  EFORT Open Rev       Date:  2021-03-01

Review 5.  Management of septic arthritis of the hip joint in adults. A systematic review of the literature.

Authors:  Giovanni Balato; Vincenzo de Matteo; Tiziana Ascione; Roberto de Giovanni; Ernesto Marano; Maria Rizzo; Massimo Mariconda
Journal:  BMC Musculoskelet Disord       Date:  2021-12-02       Impact factor: 2.362

6.  Two-Stage Total Hip Arthroplasty for Primary Advanced Septic Arthritis of the Hip in Adults.

Authors:  Zhenzhong Li; Congcong Wei; Xiangke Li; Mengxuan Yao; Huijie Li
Journal:  Biomed Res Int       Date:  2022-04-04       Impact factor: 3.411

7.  Clinical outcomes and survivorship of two-stage total hip or knee arthroplasty in septic arthritis: a retrospective analysis with a minimum five-year follow-up.

Authors:  Antonio Russo; Luca Cavagnaro; Francesco Chiarlone; Antonio Clemente; Sergio Romagnoli; Giorgio Burastero
Journal:  Int Orthop       Date:  2021-03-27       Impact factor: 3.075

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.